Showing results (1-10 of 424) with videos related to
Sort By:
Pageof 43
Surgical Oncology Clinics of North America|February 24, 2024
Tissue-Agnostic Cancer Therapy ApprovalsMohamed A Gouda, Vivek SubbiahAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 9, 2023
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid TumorsMohamed A Gouda, Vivek SubbiahCancer Journal (Sudbury, Mass.)|November 16, 2022
Strategies for Mitigating Antibody-Drug Conjugate Related Adverse Events for Precision TherapyMohamed A Gouda, Vivek SubbiahTherapeutic Advances in Medical Oncology|June 26, 2023
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancersMohamed A Gouda, Vivek SubbiahMed (New York, N.Y.)|November 12, 2022
Exportin(g) precision oncology beyond genomics with XPO1 inhibitionMohamed A Gouda, Vivek SubbiahCancer Discovery|April 18, 2023
N-of-1 Trials in Cancer Drug DevelopmentMohamed A Gouda, Lars Buschhorn, Andreas Schneeweiss, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2023
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical ImplicationsMohamed A Gouda, Blessie E Nelson, Lars Buschhorn, et al.CA: a Cancer Journal for Clinicians|May 30, 2024
The evolving landscape of tissue-agnostic therapies in precision oncologyVivek Subbiah, Mohamed A Gouda, Bettina Ryll, et al.Trends in Cancer|January 20, 2024
Impact of tissue-agnostic approvals on management of primary brain tumorsManmeet S Ahluwalia, Atulya A Khosla, Ahmad Ozair, et al.Oncoscience|September 22, 2023
Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgeryMohamed A Gouda, Filip Janku, Neeta Somaiah, et al.Pageof 43